Jean-Charles Ahomadegbe
Institut Gustave Roussy
26 Papers
668 Citations
Jean-Charles Ahomadegbe is an academic researcher from Institut Gustave Roussy. The author has contributed to research in topics: Cancer & Breast cancer. The author has an hindex of 15, co-authored 26 publications.
Chat about Author
Papers
•Journal Article
High incidence of loss of heterozygosity and abnormal imprinting of H19 and IGF2 genes in invasive cervical carcinomas. Uncoupling of H19 and IGF2 expression and biallelic hypomethylation of H19.
Sétha Douc-Rasy,Michel Barrois,S Fogel,Jean-Charles Ahomadegbe,Dominique Stehelin,Jean Coll,Guy Riou +6 more
TL;DR: The data suggest that H19 and IGF2 genes, via deletions and/or abnormal imprinting, could play a crucial role in a large proportion (58%) of cervical cancers where they may be associated with disease progression.
121
Lobular and ductal carcinomas of the breast have distinct genomic and expression profiles
François Bertucci,Béatrice Orsetti,Vincent Nègre,Pascal Finetti,Carole Rougé,Jean-Charles Ahomadegbe,Frédéric Bibeau,Marie-Christine Mathieu,Isabelle Treilleux,Jocelyne Jacquemier,Lisa Ursule,Agnès Martinec,Qing Wang,Jean Bénard,Alain Puisieux,Daniel Birnbaum,Charles Theillet +16 more
TL;DR: Comparison of array-compared genomic hybridization and cDNA microarray of a set of 50 breast tumors showed that ILCs and IDCs could be distinguished on the basis of their genomic and expression profiles suggesting that they evolve along distinct genetic pathways.
115
P73 functionally replaces p53 in Adriamycin-treated, p53-deficient breast cancer cells.
Muriel Vayssade,Hedi Haddada,Laetitia Faridoni-Laurens,Sophie Tourpin,A. Valent,Jean Bénard,Jean-Charles Ahomadegbe +6 more
TL;DR: In cells with no p53 response after ADR treatment, TAp73, but not TAp63 or ΔN‐p73/p63, may replace p53 in triggering not only apoptosis but also cell cycle arrest or DNA repair effectors such as p21, GADD45, 14‐3‐3σ and p53R2.
92
Cisplatin-induced apoptosis and p53 gene status in a cisplatin-resistant human ovarian carcinoma cell line.
Anne Fajao,Jacqueline Da Silva,Jean-Charles Ahomadegbe,Jean-Gabriel Rateau,Jean-François Bernaudin,Guy Riou,Jean Bénard +6 more
TL;DR: The data suggest that the levels of cisplatin‐DNA lesions are critical for drug sensitivity and apoptosis induction in this in vitro ovarian carcinoma model and the presence of non‐functional p53 in resistant cells might be involved in the relative failure of cisPlatin‐induced apoptosis in these cells.
63
Loss of heterozygosity, allele silencing and decreased expression of p73 gene in breast cancers: prevalence of alterations in inflammatory breast cancers.
Jean-Charles Ahomadegbe,Sophie Tourpin,Mourad Kaghad,Laurent Zelek,Muriel Vayssade,M-C Mathieu,F. Rochard,Marc Spielmann,Thomas Tursz,Daniel Caput,Guy Riou,Jean Bénard +11 more
TL;DR: LOH, allele silencing and decreased expression of the p73 gene may play a role in breast carcinogenesis, suggesting that decreased expression could be related to tumour aggressiveness.
52